Liraglutide studies: 1,219 papers with results
Page 8 of 25
- Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study.
Del Olmo-García MI · The Journal of international medical research · 2020
Randomized controlled trial · 7 results
- Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
Khoo J · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 4 results
- Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB · Diabetes · 2002
Randomized controlled trial · 11 results
- Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
Skov J · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 13 results
- Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.
Øhrstrøm CC · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 11 results
- The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Chang AM · Diabetes · 2003
Randomized controlled trial · 6 results
- Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
Rotondo A · International journal of obesity (2005) · 2013
Randomized controlled trial · 7 results
- Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study.
Herfarth H · The American journal of gastroenterology · 2024
Randomized controlled trial · 1 result
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM · Lancet (London, England) · 2018
Randomized controlled trial · 10 results
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M · Diabetic medicine : a journal of the British Diabetic Association · 2009
Randomized controlled trial · 13 results
- The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
Agersø H · Diabetologia · 2002
Randomized controlled trial · 17 results
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Mathieu C · Diabetes care · 2016
Randomized controlled trial · 14 results
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J · Diabetes, obesity & metabolism · 2009
Randomized controlled trial · 11 results
- Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
Elbrønd B · Diabetes care · 2002
Randomized controlled trial · 14 results
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
Shaman AM · Circulation · 2022
Randomized controlled trial · 18 results
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Pratley R · International journal of clinical practice · 2011
Randomized controlled trial · 8 results
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.
Nauck MA · Diabetes care · 2016
Randomized controlled trial · 14 results
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A · Diabetes, obesity & metabolism · 2011
Randomized controlled trial · 7 results
- Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Lovshin JA · Diabetes care · 2015
Randomized controlled trial · 10 results
- GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.
Hegedüs L · The Journal of clinical endocrinology and metabolism · 2011
Randomized controlled trial · 3 results
- Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M · Diabetes research and clinical practice · 2012
Randomized controlled trial · 11 results
- Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB · Diabetes care · 2010
Randomized controlled trial · 10 results
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 12 results
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C · Diabetes, obesity & metabolism · 2014
Randomized controlled trial · 7 results
- Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Watson KT · Behavioural brain research · 2019
Randomized controlled trial · 2 results
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC · Diabetes, obesity & metabolism · 2015
Randomized controlled trial · 13 results
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Marso SP · Journal of the American College of Cardiology · 2020
Randomized controlled trial · 8 results
- Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.
Wadden TA · Obesity (Silver Spring, Md.) · 2019
Randomized controlled trial · 5 results
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Niswender K · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 8 results
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
Kaku K · Diabetes, obesity & metabolism · 2010
Randomized controlled trial · 11 results
- Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
Gaborit B · The Journal of clinical endocrinology and metabolism · 2020
Randomized controlled trial · 3 results
- Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Zhang LY · Clinics and research in hepatology and gastroenterology · 2020
Randomized controlled trial · 7 results
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
Bode BW · Diabetes, obesity & metabolism · 2010
Randomized controlled trial · 11 results
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Forst T · Diabetic medicine : a journal of the British Diabetic Association · 2012
Randomized controlled trial · 10 results
- Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Smits MM · Diabetes & metabolism · 2021
Randomized controlled trial · 6 results
- Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
Arturi F · Endocrine · 2017
Randomized controlled trial · 7 results
- Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M · Diabetes · 2024
Randomized controlled trial · 12 results
- Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.
O'Donnell C · Annals of the American Thoracic Society · 2024
Randomized controlled trial · 8 results
- Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Pratley RE · Diabetes care · 2012
Randomized controlled trial · 17 results
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Smits MM · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 5 results
- Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.
Gallwitz B · International journal of clinical practice · 2010
Randomized controlled trial · 6 results
- One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
Svensson CK · Acta psychiatrica Scandinavica · 2019
Randomized controlled trial · 6 results
- Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Angelidi AM · Metabolism: clinical and experimental · 2023
Randomized controlled trial · 5 results
- No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
Hegedüs L · Diabetes care · 2018
Randomized controlled trial · 3 results
- Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Davies M · Diabetic medicine : a journal of the British Diabetic Association · 2011
Randomized controlled trial · 5 results
- Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R · Diabetes · 2018
Randomized controlled trial · 9 results
- The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Nandy D · Diabetes & vascular disease research · 2014
Randomized controlled trial · 3 results
- Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
Bode BW · The American journal of geriatric pharmacotherapy · 2011
Randomized controlled trial · 8 results
- Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.
Schiavon M · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 5 results
- Liraglutide restores impaired associative learning in individuals with obesity.
Hanssen R · Nature metabolism · 2023
Randomized controlled trial · 2 results